Ocular Therapeutix Inc. added $6 million to its Series C round.
The equity and options-based round was supported by 29 investors on aggregate, according to a Securities & Exchange Commission filing.
Ocular closed on the first $15 million of the C round in June 2009 when the company was known as I-Therapeutix Inc. The ophthalmology firm took its present name in Sept. 2009 to better reflect its mission. It has raised more than $28 million since it was founded in 2006.
The Bedford, Mass.-based company develops hydrogels for drug delivery and protecting the eye after ophthalmic procedures. In October 2010, Ocular completed a "Proof of Principle" clinical study of its moxifloxacin punctum plug, a drug delivery device for post cataract surgery.
Founder Amar Sawhney’s Eyegate Pharmaceuticals Inc. also raised $4.5 million a week before Ocular’s latest round, according to a regulatory filing.
Read our interview with Ocular Therapeutix CEO Amar Sawhney from June, 2009.
